Huge amount of capital into the pharmaceutical sector chemical drugs, Chinese medicine, biological drugs are rising alarmingly!

On May 29, the day after the two sessions of the National People's Congress, Premier Li Keqiang presided over an executive meeting of the State Council to determine the division of tasks in the Report on the Work of the Government, and called for strict policy and implementation of the work to complete the tasks of economic and social development for the whole year.
to promote the good practices of active service enterprises in epidemic prevention and control, eliminate the control measures that are not needed for prevention and control, and explicitly request that the complexity of the current situation should be fully estimated, the global epidemic and new changes in the economic situation should be closely followed, and attention should be paid to understanding and solving problems encountered in the implementation of policies, and timely and perfecting policies.
and the capital market after last week's two sessions of the "wait-and-see period", the first day of this week's pharmaceutical section of the overall performance, Chinese medicine, biological drugs, chemical drugs generally rose, frequent financial flows.
Biomedicine According to the SASAC public number, from May 30, The National Pharmaceutical Group of China Bio-New Crown Inactivated Vaccine Workshop will be fully disinfected and into the final preparations before production.
during the two sessions, Yu Qingming, chairman of China Pharmaceutical Sinbet Holdings, said in an interview with the media that in order to achieve large-scale production of the new coronavirus vaccine as soon as possible, China BioBeijing has completed the construction of a new crown vaccine workshop, Wuhan Institute will be completed in September this year. As a result
, the overall biomedicine sector today has been significantly affected by the "vaccine" and has increased significantly.
CRO, vaccines, animal vaccines, biopharmaceuticals and other main business have increased to varying degrees.
may be derived from the correct transmission and interpretation of the information of the two sessions, the author predicted that for a long time, biopharmaceuticalwill will be much attention, especially in which the "vaccine" section.
but in the investment process also need to pay attention to the arrival of market expectations! At the same time, with the large amount of funds inthesively in the field of biopharmaceuticals, a large number of capital outflows also appeared, the most important of which is the chemical industry in the "Huahai Pharmaceutical."
today, the chemical drug sector as a whole floated 2.1%, Huahai Pharmaceutical10.01% rose and stopped, the increase of more than 5% of the enterprises reached 11, 112 chemical pharmaceutical enterprises in only 7 enterprises fell, and the highest degree of decline in the same and pharmaceutical industry is only 2.01%, can be described as a good.
and for Huahai Pharmaceuticals, most of the small partners are not surprised.
according to May 31, 2020, Changjiang Securities in the release of the research report, said that in the past few years, Huahai Pharmaceutical, domestic consistency evaluation, volume procurement, environmental protection, Europe and the United States gene toxic impurity control standards to improve many policies, the beneficiaries are pointed to in science and technology, quality, scale, environmental protection and other aspects have excellent strength of high-quality pharmaceutical manufacturers, with more and less negative news, really have a bad life.
but the current Huahai, after a long period of recovery, is gradually out of the haze of impurities, business is gradually returning to a healthy state.
in the new industrial environment, Huahai characteristics of raw materials, domestic preparations, preparations export three business sectors are facing good growth opportunities.
multiple drivers, making the company's continued rapid growth in the coming years provide ample guarantee.
domestic preparation business as the primary point of view of Huahai at this stage, business growth and profit elasticity are worthy of high expectations.
starting from the next round of collection, the company's varieties will begin to be fully presented as "light feet" state, basically will be newly approved varieties.
no matter how many markets are seized and how many sales are realized, they will be represented as pure increments.
and the field of specialising API has changed significantly due to the guidance of downstream preparation customers in the procurement of API.
quality, environmental protection and safety have become its core concerns.
taking into account the high technical barriers of specialty api, the new production capacity into a longer cycle, high business climate or will continue in the future longer cycle, Huahai benefits greatly.
Chinese medicine finally, as in the two sessions by the members of the most, by the national leadership mentioned the most "Chinese medicine", today's performance is obviously not as good as the previous two, as of June 1 at 3 pm, the overall increase of Chinese medicine section 1.79%, the highest increase in "Scent Yin Pharmaceuticals" is only 5.88 percent.
, however, in 66 Chinese medicine enterprises only "East A gum" one fell, and the range of more than 2%.
in addition, the outbreak of the largest beneficiaries of the Yingling pharmaceutical industry, today is the response flat, up 1.86 percent of the results, really sorry for Chinese medicine "popular ity of the first person" title.
society is a strange scene: on the one hand, the industry big people push "Chinese medicine", on the other hand, the chinese medicine capital market does not pay the bill, medicine overall good situation, Chinese medicine always appears to have such a hint of violation, performance is really general.
perhaps, this is also due to the previous outbreak on the pharmaceutical sector has a major impact, after the "enthusiasm", the "calm" is always to come.
perhaps most investors at present are different degrees of view, to the current market, the valuation of Chinese medicine has entered a temporary apex stage, the degree of short-term rise and probability are not high, investment in "Chinese medicine" cost-effective.
compare the frequency of Chinese medicine during the two sessions, a phrase "contrary to expectations" is really appropriate.
.